Free Trial

Recursion Pharmaceuticals (RXRX) News Today

Recursion Pharmaceuticals logo
$6.04 -0.23 (-3.67%)
(As of 11/20/2024 ET)
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 12-Month Low - Here's Why
Recursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low - Here's Why
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% After Insider Selling
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.9% on Insider Selling
Recursion Pharmaceuticals, Inc. stock logo
Sumitomo Mitsui Trust Group Inc. Sells 220,302 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Sumitomo Mitsui Trust Group Inc. decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 2.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,766,728 shares of the co
Recursion Pharmaceuticals, Inc. stock logo
Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Pier 88 Investment Partners LLC raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 442.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,910 shares of the company's stock after pu
Leerink Partnrs Has Bullish Outlook for RXRX FY2024 Earnings
Recursion Pharmaceuticals, Inc. stock logo
Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Baillie Gifford & Co. trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 5.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,239,870 shares of the company's stock af
Recursion Pharmaceuticals, Inc. stock logo
Leerink Partnrs Has Positive Outlook of RXRX FY2024 Earnings
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings estimates for shares of Recursion Pharmaceuticals in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the
Recursion Pharmaceuticals, Inc. stock logo
ARK Investment Management LLC Has $215.95 Million Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
ARK Investment Management LLC lifted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 16.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,769,186 shares of th
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday.
TD Cowen Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals, Inc. stock logo
Mirae Asset Global Investments Co. Ltd. Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Mirae Asset Global Investments Co. Ltd. grew its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1,173.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,539 shares o
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (RXRX) to Release Earnings on Wednesday
Recursion Pharmaceuticals (NASDAQ:RXRX) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.6% Following Insider Selling
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.6% Following Insider Selling
Recursion Pharmaceuticals, Inc. stock logo
Tina Marriott Sells 6,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) COO Tina Marriott sold 6,000 shares of the company's stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company's stock, valued at $3,288,380.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.1% - Here's What Happened
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 5.1% - Here's What Happened
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - Here's What Happened
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 0.8% Higher - What's Next?
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.2% - Here's Why
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.2% - Time to Sell?
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 0.9% - Should You Sell?
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.9% - Should You Sell?
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of "Hold" by Brokerages
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has received a consensus recommendation of "Hold" from the six analysts that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 1.5% - Here's What Happened
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.5% - Here's Why
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.6% - Should You Sell?
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 3.6% - Should You Sell?
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 2.9% - Still a Buy?
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 2.9% Higher - What's Next?
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 3.3% - Here's Why
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.3% - What's Next?
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.9% - Still a Buy?
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 1.9% Higher - Here's Why
Recursion Pharmaceuticals, Inc. stock logo
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4% - Should You Sell?
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.4% - What's Next?
Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

RXRX Media Mentions By Week

RXRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RXRX
News Sentiment

0.13

0.45

Average
Medical
News Sentiment

RXRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RXRX Articles
This Week

11

7

RXRX Articles
Average Week

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:RXRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners